Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81
Document › Details

Cytos Biotechnology AG. (8/12/15). "Press Release: Cytos Exclusively Licenses Its VLP Platform for the Treatment of Cancer to Checkmate Pharmaceuticals LLC". Schlieren.

Organisations Organisation Cytos Biotechnology AG
  Today Kuros Biosciences AG (SIX: KURN)
  Group Kuros (Group)
  Organisation 2 Checkmate Pharmaceuticals LLC
  Today Checkmate Pharmaceuticals Inc. (CMPI)
  Group Checkmate Pharmaceuticals Inc. (CMPI)
Products Product VLP technology (virus-like particle technology)
  Product 2 CMP-001 (formerly CYT003) (Checkmate Pharma / Kuros / Cytos)
Index terms Index term Checkmate–Cytos Biotechnology: cancer immunotherapy, 201508– excl license to CYT003 + VLP technology for cancer $90m milestones + royalties
  Index term 2 Checkmate–SEVERAL: investment, 201508 financing round Series A $20m from Sofinnova Ventures + venBio
Persons Person Itin, Christian (Autolus 201603– CEO before Cytos 201211–201601 + Micromet 1999–2012 CEO + Co-founder + Zyomyx Inc)
  Person 2 Welten, Harry (Cytos Biotechnology 201203 CFO)

Cytos Biotechnology Ltd. (SIX:CYTN) (“Cytos”) announced today that it executed an exclusive license agreement in the field of oncology granting Checkmate Pharmaceuticals LLC, Cambridge, MA, USA (“Checkmate”) exclusive access to Cytos’ clinically validated product candidate CYT003 as well as its VLP platform and to technology related to oligonucleotide synthesis.

Cytos may receive up to USD 90 million in development milestones and may receive up to double-digit royalties on net sales from successfully developed products.

“We are excited about the potential of our immunologically active VLP platform in the field of immune-oncology and believe that Checkmate is well positioned to advance treatment options for patients with cancer,” commented Christian Itin, Chairman and CEO of Cytos.

For further information, please contact:

Cytos Biotechnology Ltd
Harry Welten, MBA
Chief Financial Officer
Tel: +41 44 733 46 46

About Cytos Biotechnology Ltd

Cytos is a public biopharmaceutical company located in Schlieren (Zurich), Switzerland. The Company is listed according to the Main Standard on the SIX Swiss Exchange Ltd under the symbol CYTN. Website:

About Checkmate

Checkmate Pharmaceuticals is a research and development company pursuing a novel approach to specifically activating the innate arm of the immune system to recognize and ultimately destroy tumor cells. The company is leveraging their expertise and the vast body of knowledge in the field of CpG oligonucleotides and is validating an approach that will combine the ability of CpG DNA to activate an anti-tumor T cell response with checkpoint inhibition to overcome a tumor’s ability to mute the immune response. Checkmate’s founder and CEO, Dr. Art Krieg, discovered CpG DNA in 1994 and since then CpG DNAs have been administered to thousands of humans showing potent immune activation and an excellent safety profile. Checkmate is a privately held company headquartered in Cambridge, Mass. Information regarding Checkmate is available on the company's web site at

Forward Looking Statements

This media release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. You are urged to consider statements that include the words “will” or “expect” or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include scientific, business, economic and financial factors, Against the background of these uncertainties, readers should not rely on forward-looking statements. The Company assumes no responsibility for updating forward-looking statements or adapting them to future events or developments.

Cytos Biotechnology Ltd. Wagistrasse 25 8952 Schlieren/Switzerland
Phone: +41 44 733 47 47 Fax: +41 44 733 47 40

Record changed: 2016-04-03


Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

More documents for Kuros (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture ConsulTech GmbH Berlin Grant Application and Coordination 650x80px

» top